Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Alprazolam

FDA-approved product (tablet, oral), marketed as Alprazolam, Niravam, Xanax and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Alprazolam
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety
  • Anxiety disorder
  • Generalized anxiety disorder
  • Panic disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzodiazepine derivatives
FDA pharmacologic class
Benzodiazepine FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Alprazolam in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Alprazolam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Staccato Alprazolam Abuse Liability

    NCT00603980 · start 2008-01

    Registered record
    Registry ID
    NCT00603980
    Conditions
    Abuse Liability of Staccato Alprazolam
    Interventions
    Inhaled placebo + oral placebo; Inhaled alprazolam 0.5 mg; Inhaled alprazolam 1 mg; Inhaled alprazolam 2 mg; Oral alprazolam 1 mg; Oral alprazolam 2 mg; Oral alprazolam 4 m; Oral alprazolam 2 mg qualifying session; Oral placebo qualifying session
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-01
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAbuse Liability of Staccato Alprazolam
    InterventionInhaled placebo + oral placebo; Inhaled alprazolam 0.5 mg; Inhaled alprazolam 1 mg; Inhaled alprazolam 2 mg +5 more
    PhasePhase 1
    Registry statusCompleted

  • ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder

    NCT00613067 · start 2007-12

    Registered record
    Registry ID
    NCT00613067
    Conditions
    Generalized Anxiety Disorder
    Interventions
    escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-12
    Completion
    2010-05
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeneralized Anxiety Disorder
    Interventionescitalopram
    PhaseNot applicable
    Registry statusCompleted

  • Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects

    NCT00580190 · start 2007-09

    Registered record
    Registry ID
    NCT00580190
    Conditions
    Healthy
    Interventions
    alprazolam; Placebo; PF-00572778
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2007-09
    Completion
    2008-02
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionalprazolam; Placebo; PF-00572778
    PhasePhase 1
    Registry statusTerminated

  • Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

    NCT00574639 · start 2007-07

    Registered record
    Registry ID
    NCT00574639
    Conditions
    Type 1 Diabetes
    Interventions
    Alprazolam; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2007-07
    Completion
    2016-06
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetes
    InterventionAlprazolam; Placebo
    PhaseEarly phase 1
    Registry statusCompleted

  • Staccato Alprazolam in Panic Attack

    NCT00477451 · start 2007-05

    Registered record
    Registry ID
    NCT00477451
    Conditions
    Treatment of Induced Panic Attack
    Interventions
    Inhaled placebo; Inhaled alprazolam 1 mg; Inhaled alprazolam 2 mg; IV doxapram
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-05
    Completion
    2008-04
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment of Induced Panic Attack
    InterventionInhaled placebo; Inhaled alprazolam 1 mg; Inhaled alprazolam 2 mg; IV doxapram
    PhasePhase 2
    Registry statusCompleted

  • A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder

    NCT00555139 · start 2007-03-27

    Registered record
    Registry ID
    NCT00555139
    Conditions
    Social Phobia
    Interventions
    GSK561679 tablet; GW876008 tablet; alprazolam; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-03-27
    Completion
    2008-01-10
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSocial Phobia
    InterventionGSK561679 tablet; GW876008 tablet; alprazolam; Placebo
    PhasePhase 1
    Registry statusCompleted

  • To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.

    NCT00426608 · start 2006-10-06

    Registered record
    Registry ID
    NCT00426608
    Conditions
    Depressive Disorder and Anxiety Disorders
    Interventions
    metyrapone; alprazolam; placebo; GSK561679
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-10-06
    Completion
    2007-01-08
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder and Anxiety Disorders
    Interventionmetyrapone; alprazolam; placebo; GSK561679
    PhasePhase 1
    Registry statusCompleted

  • D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD

    NCT00356278 · start 2006-09

    Registered record
    Registry ID
    NCT00356278
    Conditions
    Stress Disorder, Post Traumatic
    Interventions
    D-Cycloserine; Alprazolam; Virtual Reality Exposure Therapy; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2006-09
    Completion
    2014-06
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStress Disorder, Post Traumatic
    InterventionD-Cycloserine; Alprazolam; Virtual Reality Exposure Therapy; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.

    NCT00368745 · start 2006-09

    Registered record
    Registry ID
    NCT00368745
    Conditions
    Generalized Anxiety Disorder
    Interventions
    Pregabalin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-09
    Completion
    2008-08
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeneralized Anxiety Disorder
    InterventionPregabalin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder

    NCT00921063 · start 2005-11

    Registered record
    Registry ID
    NCT00921063
    Conditions
    Generalized Anxiety Disorder
    Interventions
    PD 0332334; PD 0332334; placebo; Alprazolam extended release
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-11
    Completion
    2006-07
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeneralized Anxiety Disorder
    InterventionPD 0332334; PD 0332334; placebo; Alprazolam extended release
    PhasePhase 2
    Registry statusCompleted

  • Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder

    NCT00266409 · start 2005-10

    Registered record
    Registry ID
    NCT00266409
    Conditions
    Generalized Anxiety Disorder; Panic Disorder
    Interventions
    Niravam; SSRI/SNRI
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-10
    Completion
    2006-06
    Enrolment
    418

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeneralized Anxiety Disorder; Panic Disorder
    InterventionNiravam; SSRI/SNRI
    PhasePhase 4
    Registry statusCompleted

  • A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions

    NCT00865657 · start 2005-09

    Registered record
    Registry ID
    NCT00865657
    Conditions
    Healthy
    Interventions
    Alprazolam 3 mg Extended Release Tablets, single dose; XANAX XR® 3 mg tablets, single dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-09
    Completion
    2005-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAlprazolam 3 mg Extended Release Tablets, single dose; XANAX XR® 3 mg tablets, single dose
    PhasePhase 1
    Registry statusCompleted

  • A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions

    NCT00865761 · start 2005-09

    Registered record
    Registry ID
    NCT00865761
    Conditions
    Healthy
    Interventions
    Alprazolam 3 mg Extended Release Tablets, single dose; XANAX XR® 3 mg tablets, single dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-09
    Completion
    2005-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAlprazolam 3 mg Extended Release Tablets, single dose; XANAX XR® 3 mg tablets, single dose
    PhasePhase 1
    Registry statusCompleted

  • Staccato Alprazolam Single Dose PK

    NCT00444522 · start 2005-06

    Registered record
    Registry ID
    NCT00444522
    Conditions
    Healthy
    Interventions
    Alprazolam thermal aerosol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-06
    Completion
    2005-08
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAlprazolam thermal aerosol
    PhasePhase 1
    Registry statusCompleted

  • Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions

    NCT00830024 · start 2005-06

    Registered record
    Registry ID
    NCT00830024
    Conditions
    Healthy
    Interventions
    Alprazolam Extended-Release 3 mg Tablets; Alprazolam Extended-Release 3 mg Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-06
    Completion
    2005-06
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAlprazolam Extended-Release 3 mg Tablets; Alprazolam Extended-Release 3 mg Tablets
    PhasePhase 1
    Registry statusCompleted